Trials / Completed
CompletedNCT00606749
Use of KC706 for the Treatment of Pemphigus Vulgaris
A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Kemia, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether KC706 is effective in the prevention and healing of blisters in patients with pemphigus vulgaris, while the patient remains on stable doses of corticosteroids and/or immunosuppressants.
Detailed description
The present study is designed to follow-up on pre-clinical observations that administration of KC706 is associated with prevention of the development of lesions in a mouse model of PV. Patients participating in this study will be those with active disease in spite of ongoing treatment with corticosteroids and/or immunosuppressive agents. The dose chosen for this clinical study is 300 mg once daily. The primary assessment of interest will be pemphigus lesion status during dosing with KC706.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KC706 | 300 mg once daily (QD) for 12 weeks. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2008-02-05
- Last updated
- 2008-06-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00606749. Inclusion in this directory is not an endorsement.